Next Gen. CAR-T

Although great success has been made in the treatment of blood cancer using CAR-T cells, much more challenges remains for the treatment of solid tumors. Unlike in blood cancer especially leukemia, the CAR-T should penetrate into the solid tumor and face the hostile microenvironment. Therefore, novel strategies such as incorporating chemokine receptor or cytokines such as IL-12 that can bridge innate and adaptive immune should be applied to increase the efficacy of CAR-T cells against solid tumors.